Strategic Initiatives
12380 stories
·
45 followers

Did Mamdani Really Think He Could Arrest Netanyahu?

1 Share
  • Mamdani and Netanyahu: Mayor Zohran Mamdani acknowledged that he lacks authority to arrest Israeli prime minister Benjamin Netanyahu, despite previously promising to do so.
  • Israel as a political symbol: Gaza has become a purity test for highly engaged Democratic voters, with accusations involving Israel shaping judgments about political trustworthiness.
  • Prediction-market advertising: Polymarket and Kalshi operate under financial regulations that leave their marketing relatively lightly supervised, allowing potentially misleading promotions.
  • Influencer promotions: Reported campaigns used young influencers to publicize supposed winnings, sometimes without disclosing that the influencers were paid.
  • Small-business reforms: New York proposed simplifying outdoor-dining approvals, sidewalk-display licenses, barber-shop renewals, and restaurant permits, though the changes address only a small portion of the city’s regulatory burden.
  • Additional coverage: The newsletter highlights research on New York’s special-education budget crisis, artificial-intelligence policy, NYCHA, philanthropy, education, legal institutions, and baseball history.



July 24, 2026

Forwarded this email? Sign up for free to have it sent directly to your inbox.  

City Journal

Good morning,

 

Today, we’re looking at Mayor Zohran Mamdani’s anti-Israel views, prediction market ads, and New York City’s small business regulations.

 

Write to us at editors@city-journal.org with questions or comments.

Now, on to the news…

Mamdani and the Left’s Israel Fantasy 

Zohran Mamdani

Photo credit: Anadolu / Contributor / Anadolu via Getty Images

After long promising that he would arrest Israel Prime Minister Benjamin Netanyahu if he ever came to New York City, Mayor Zohran Mamdani admitted in a video earlier this week that he did not have the authority to do so.

Did he really think he could?

Maybe. Mamdani has been anti-Israel since his time in college, and as mayor, has seized every possible opportunity to take jabs at Israel and Zionists. But his supporters still view his willingness to charge Netanyahu with genocide as a win—showing just how fixated on Israel the far Left has become.

“For highly activated Democratic voters, Gaza has become a unifying symbol of everything they identify as wrong with America and the world more broadly,” Charles Fain Lehman writes. “For these voters, Gaza is a kind of purity test. If you aren’t willing to mouth the shibboleth ‘Israel is committing a genocide,’ then you must be beholden to the dark forces that control our government. You’re intrinsically untrustworthy.”

Read more.

Prediction Market Ads Are Out of Control

Apart from baseline private-sector rules from the Federal Trade Commission (FTC), prediction-market platforms like Polymarket and Kalshi are free to advertise however they wish. They’re technically investment platforms, yes, but they fall under the Commodity Futures Trading Commission (CFTC), which is focused on regulating derivatives, not marketing.

“The result has been a flood of misleading and deceptive ads that would be out of bounds for any other financial firm,” Jonathan D. Cohen and Isaac Rose-Berman write.

Polymarket reportedly set up websites that young influencers could use to post fake wins on social media. Kalshi reportedly paid college-aged influencers to brag about their wins—and most of them didn’t disclose that they were paid.

“The companies advertise this way because it works,” Cohen and Rose-Berman observe. “A generation of young people are becoming gamblers, not necessarily because they are excited to gamble, but because they fear missing out on the winnings their peers seem to be raking in.”

Read more about the ads.

/ Read More
/ Share

Mamdani Moves to Help New York’s Small Businesses—But He Could Do More 

Earlier this week, New York Mayor Zohran Mamdani unveiled an initiative aimed at reforming the city’s onerous small business regulations. The suggested reforms include axing the multilayered process a restaurant must go through to establish outdoor seating; lifting the license bodegas must obtain for displaying items on the sidewalk; extending barber shop licenses from one year to three; cutting the duplicative permits restaurants need for serving different types of food; and more.

“These reforms are commendable, but they amount to a few grains of sand on New York City’s vast regulatory beach,” Jarrett Dieterle writes. Read where he thinks they fall short.

/ Editors Picks

/ Reader Spotlight

“Thomas Sowell has written about similar schools in the U.S.—schools that demand proper behavior and get similarly good results. I don’t know whether those schools have since been destroyed by progressive people and policies. Can’t have a good example set when trying to achieve ‘social justice.’

A quarterly magazine of urban affairs, published by the Manhattan Institute, edited by Brian C. Anderson.

Copyright © 2026 Manhattan Institute, All rights reserved.

Donate

City Journal is a publication of the Manhattan Institute for Policy Research (MI), a leading free-market think tank. Are you interested in supporting the magazine? As a 501(c)(3) nonprofit, donations in support of MI and City Journal are fully tax-deductible as provided by law (EIN #13-2912529).

Read the whole story
bogorad
4 hours ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

ChatGPT starts blocking direct requests to copy an author's style - Ars Technica

1 Comment

LLM (google/gemini-3.5-flash-lite) summary:

  • Style Refusal Cuteness: openai software now whines about copying specific authors while still spitting out generic garbage that captures the exact same vibe to appease greedy writers crying over imaginary property.
  • Legal Panic Stations: tech monopolists are sweating bullets over lawsuits from bourgeois novelists demanding protection for their precious words while using identical avoidance tactics for dead people too.
  • Vague Law Exploitation: capitalist courts protect specific expressions rather than intangible styles, leaving corporate lawyers scrambling to exploit loopholes where ai mimicry crosses into substantial similarity.
  • Academic Handwringing: state university parasites are making bank studying how easily digital tools replicate individual bourgeois flair without paying proper tribute to the creative class.
  • Guild Protectionism: professional writers associations are publishing hypocritical ethics guides to protect their own profit margins from automated competition under the guise of mutual respect.
  • Public Humiliation: lazy hacks keep getting caught red handed publishing unedited machine slop that explicitly brags about ripping off popular genre fiction peddlers.
  • Inconsistent Competitor Policies: rival tech cartels handle intellectual property theft differently, with some chatbot programs totally refusing while others happily plagiarize everything in sight.
  • User Meltdowns: entitled prompt engineers are crying on public forums because their automated plagiarism workflows got slightly inconvenienced by corporate safety filters.

Story text
Size Width * Links
* Subscribers only
  Learn more

OpenAI’s ChatGPT is now refusing requests to generate text that directly mimics the style of famous authors. When asked to do so, the popular LLM instead offers a response that draws on the “broad qualities” of those authors “while remaining distinct in its own voice,” for example.

This morning, Ars received the following response to a test prompt asking for a story introduction in the style of Stephen King:

I can definitely write with the hallmarks of atmospheric, character-driven horror and small-town dread, but I can’t write in Stephen King’s exact style or closely imitate his distinctive voice. Here’s an original opening that captures a similar feeling while remaining its own…

In testing, ChatGPT generated similar dodges for other authors both living (J.K. Rowling, Amy Tan) and dead (Charles Dickens, Ernest Hemingway). An analysis published by No Latency earlier this month found the same behavior for living authors but found ChatGPT complied with style-copying requests for deceased authors.

In refusing to directly copy the “exact style” of various authors, ChatGPT offered instead to capture an overall “feeling” by incorporating some of the common features found in those authors’ work. That may seem like a distinction without a real difference at first glance. But the slight alteration could be legally important as OpenAI continues to fight a number of lawsuits brought by book authors alleging large-scale copyright infringement by models trained on their work. One of those suits specifically cites ChatGPT’s “uncanny ability to generate text similar to that found in copyrighted textual materials,” for instance. An OpenAI spokesperson did not respond to a request for comment from Ars Technica.

In the US, copyright law generally protects only a specific expression of an idea, not the more intangible style of an author. But an AI-generated stylistic imitation could become infringing if it becomes “substantially similar” to the work of the original author.

“We’ve never had a situation in which this personal style of individual creators could be imitated as well and as inexpensively as we now have with AI,” George Washington University Law School Professor Robert Brauneis told Bloomberg Law.

Staying out of trouble

In a “best practices” document published by the Authors Guild, the professional organization urges writers to “respect your fellow authors and do not use generative AI to purposely copy or mimic the unique styles, voices, or other distinctive attributes of other writers’ works in ways that harm the value of their works or attempt to profit from them. Apart from the ethical issues, mimicking a fellow writer’s unique voice or style could subject you to claims of unfair competition or copyright infringement.”

LLMs’ penchant for style mimicry has led to some prominent public issues in the recent past. Last year, author Lena McDonald faced widespread criticism when her book included an apparent AI-generated response that read, “I’ve rewritten the passage to align more with [fellow genre author] J. Bree’s style…”

It’s not hard to find other examples of writers using LLMs to copy another author’s style in the years since ChatGPT’s rise. There have been multiple academic studies analyzing various LLMs’ capabilities on this score, both with and without fine-tuning.

When it comes to image generation, OpenAI prominently notes that its DALL·E 3 model “is designed to decline requests that ask for an image in the style of a living artist.” But an extensive OpenAI model spec published in December doesn’t include any clearly stated prohibitions against replicating copyrighted material or mimicking style in written responses.

Not all major LLMs treat these style imitation requests the same way, though. No Latency’s study found that Google’s Gemini consistently complied with requests to copy an author’s style, while Perplexity AI’s models consistently refused such requests and redirected them (à la ChatGPT). Somewhere in the middle, both Anthropic’s Claude and Microsoft’s Copilot complied with the style-mimicry requests but offered stated qualifications suggesting “an awareness of the imitation issue,” according to the authors.

For some longtime OpenAI users, though, the changes to ChatGPT’s stylistic rules are already causing headaches. “Now Ms. GPT says she can’t generate content in the style of specific authors,” Reddit user Dazzling-Major-5620 wrote recently. “My prompts were soooo specific and I got exactly what I wanted out of them… I have no idea how to get around this other than maybe feed it prose I already edited that’s technically mine?”

Photo of Kyle Orland
Kyle Orland Senior Gaming Editor
Kyle Orland Senior Gaming Editor
Kyle Orland has been the Senior Gaming Editor at Ars Technica since 2012, writing primarily about the business, tech, and culture behind video games. He has journalism and computer science degrees from University of Maryland. He once wrote a whole book about Minesweeper.
Read the whole story
bogorad
4 hours ago
reply
You don't hate the copyright industry enough. You think you do, but you don't.
Barcelona, Catalonia, Spain
Share this story
Delete

Exclusive | David Fox Upended ‘Big Law’ Once. He Plans to Do It Again Using AI. - WSJ

1 Share

LLM (google/gemini-3.5-flash-lite) summary:

  • Legal Industry Disruption: david fox co-founded irving technology to power an ai-based law firm, attempting to upend the legal profession through software automation.
  • Corporate Playbook: the veteran dealmaker previously engineered the growth strategy that turned kirkland & ellis into the world's largest law firm by revenue.
  • Artificial Intelligence Focus: irving employs only a handful of lawyers and relies on software trained to handle tasks comparable to a senior associate.
  • Venture Capital Backing: the startup is funded by prominent investors, including narya capital, addition, and antiportfolio ventures.
  • Structural Separation: the enterprise utilizes a management services organization model to separate the legal practice from the technology entity, enabling outside investment.
  • Market Competition: elite firms are heavily investing in proprietary ai platforms or partnering with tech giants to combat the threat of legal-tech upstarts.
  • Global Background: fox was born in new york, raised in israel, returned to the u.s. for his legal career, and previously led major mergers at skadden arps.
  • Extracurricular Ventures: beyond his legal-tech pursuits, fox manages a venture capital firm, collects motorcycles, and supports an ai center at the hebrew university of jerusalem.

Portrait of David Fox, a retired lawyer.David Fox co-founded a legal-tech company that is powering an AI-based law firm.

By

Lauren Thomas

| Photography by Roshni Khatri for WSJ

July 26, 2026 7:00 pm ET

David Fox upended the legal industry once before. He hopes to do it again. 

The longtime dealmaker is credited with devising the playbook that helped make Kirkland & Ellis the biggest law firm in the world. His new pursuit could one day put him in competition with Kirkland and its peers. 

Fox, 68, co-founded a software company, Irving Technology, that is powering a newly launched law firm, called Irving, which employs only a handful of lawyers and primarily relies on artificial intelligence. 

“I hope I have one more revolution left in me,” Fox said in an interview. 

Fox believes Irving—and similar ventures—could permanently change how legal services are delivered to clients and funded. Elite law firms are just beginning to game out how AI could remake their business models. The need for investment has already prompted many to explore alternative ownership structures, and industry leaders have been debating how the technology could shrink head count or alter fee structures over time.

Fox is in the camp that believes AI will free lawyers from repetitive tasks and let them focus on the thorniest issues. He says clients, in turn, will be charged less money. Irving’s software is at a basic level trained to be about as smart as a high-performing senior-level associate. 

Irving will be going up against a bevy of other legal AI upstarts and the major AI developers themselves as well as established firms, each of which have been charting their own futures with AI. 

Kirkland & Ellis recently said it set aside $500 million to create its own AI platform rather than rely on tools also used by competitors, while Freshfields struck a deal with Anthropic to co-build specialized AI applications. Cleary Gottlieb bought legal-tech firm Springbok AI, bringing a team of AI engineers in-house.

Several so-called AI-native law firms are already in operation. Many, like Irving, involve two distinct business entities—one housing the lawyers and one housing the technology, which allows for outside investors in the latter. 

One called Norm Law, which has hired senior lawyers away from firms including Ropes & Gray and Sidley Austin, is powered by an AI company backed by Bain Capital and Blackstone. Another legal-tech company backed by General Catalyst is behind a new AI-powered firm called Eudia Counsel. Then there are off-the-shelf products such as Harvey, Legora and CoCounsel that are quickly becoming ubiquitous across the industry. 

A dealmaker

Fox was born in New York, but his family moved to Israel when he was 9 years old. He moved back to the U.S. in 1983 to launch his legal career at Skadden, Arps, Slate, Meagher & Flom. 

Fox worked at Skadden for more than two decades, rising up the ranks to become the firm’s most-senior partner and among the highest-paid lawyers, working on marquee deals including the $6.6 billion leveraged buyout of Toys “R” Us in 2005. 

In 2009, he shocked the legal industry by departing Skadden for Kirkland & Ellis, which at the time had only a nascent mergers-and-acquisitions practice. He brought with him Daniel Wolf, a younger Skadden partner on the rise. 

Fox, with the help of then-chairman Jeff Hammes, formulated a plan to make Kirkland a juggernaut in M&A. It revolved around resetting the culture at the firm’s New York office and plucking up-and-coming lawyers from other firms. He also steered lawyers to focus on bigger deals.

David Fox stands with his arm crossed in front of him in his apartment.Fox believes AI will free up lawyers to focus on the thorniest issues.

By 2020, when Fox stepped down from the firm’s executive committee in keeping with the firm’s age limits, Kirkland was working on more deals annually than any other firm. Fox said the new leadership team has since taken Kirkland to even greater heights. Last year, it helped Kirkland become the first law firm to crack $10 billion in annual revenue.

Fox, who now splits his time mostly between Miami and the New York area, says leaving Kirkland was never meant to be a formal retirement. He is keeping busy with projects beyond Irving, including a small venture-capital firm, Antiportfolio Ventures, that makes investments in legal-tech companies such as Sandstone and Patlytics. (Fox’s other partners at the VC firm are Ryan Morgan and Mike Devlin.)

He also finds time for dayslong biking excursions on his collection of motorcycles, and spending time with his wife, who works in furniture design, and their 22-year-old daughter. He is in the early stages of building a center for AI at the Hebrew University of Jerusalem School of Law, where he studied.

The industry’s big question

Irving Technology has raised a small sum of money so far from investors including Narya Capital, the venture-capital firm co-founded by JD Vance before he entered politics, the New York-based venture firm Addition, Hammes and Fox’s Antiportfolio Ventures. Its three other co-founders are engineers with backgrounds at technology and defense companies, including Palantir Technologies.

Irving, the associated law firm based in New York, currently employs fewer than 10 people—a mix of lawyers and engineers—and has been running in stealth for a few weeks now, having already advised on a handful of small deals before its official debut at a later date.

Irving Technology’s software was trained on existing large language models with input from practicing deal lawyers. It is meant to be able to handle tasks such as pulling research or drafting documents, freeing up senior lawyers to focus on winning new business and advising clients.

“A great legal partner’s superpower was always knowing what deserves attention in a deal and what doesn’t,” Fox says. 

Fox says he will be involved in the law firm but doesn’t have a defined role and isn’t practicing as a lawyer himself. Over time, he says, he believes the law firm will hire more senior lawyers and work on bigger deals.

Books titled "The Infinity Machine," "Beyond Inheritance" and "For Blood and Money."Some of the books in Fox's apartment in Manhattan.

Irving and its peers employ a so-called management services organization, or MSO, model, which keeps the legal side separate from the piece that houses technology and any intellectual property. That allows for backing from nonlawyer investors such as private-equity firms. It also sets up the technology firms to eventually go public or pursue other exits, similar to what is happening in the accounting industry.

McDermott Will & Schulte, the culmination of a 2025 merger between big law firms in Chicago and New York, is one of a number of established firms that have been considering converting to an MSO structure, according to people familiar with the matter.

A handful of states, meanwhile, have loosened restrictions barring law firms from taking outside money or are considering doing so. Arizona in 2020 became the first state to eliminate the rules entirely.

Fox says these shifts are “challenging decades-old assumptions about staffing, profitability and client value.”

Still, he said the need for talented lawyers won’t go away: “The question becomes: ‘Do I need 5,000 people who are really talented? Or can I do it with 20 people?’”

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Appeared in the July 27, 2026, print edition as 'Lawyer Who Upended Profession Is Doing It Again'.

Lauren Thomas is the lead reporter on M&A and shareholder activism for The Wall Street Journal in New York. She consistently breaks market-moving news about the biggest deals across all industries. Some of her scoops have included the $55 billion leveraged buyout of Electronic Arts, Union Pacific's more than $70 billion deal for Norfolk Southern, Exxon Mobil’s $60 billion deal for Pioneer Natural Resources, Google parent Alphabet's $32 billion deal for Wiz, Mars’s $30 billion deal for food maker Kellanova, and Sycamore's $10 billion take-private of Walgreens. She also frequently scoops the biggest proxy fights in corporate America, including recent battles at Starbucks, Disney and Southwest Airlines.

Before joining the Journal in October 2022, Lauren covered the retail and consumer industries at CNBC. There, she broke news on companies ranging from Target to Macy’s to Peloton, and she regularly appeared on CNBC TV programming.

A native of Spartanburg, S.C., Lauren graduated with high honors from the University of North Carolina at Chapel Hill, where she studied business journalism and Spanish.

Read the whole story
bogorad
4 hours ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

Are Autonomous Cars More Dangerous Than Uber Drivers?

1 Share
  • Safety comparison: Waymo reports 0.71 injury-causing crashes per million miles, compared with 2.15 for New York City taxis, Uber, and Lyft vehicles.
  • Fatal-crash record: Waymo, citywide drivers, and for-hire vehicles are statistically similar on fatal crashes, though the available data are limited.
  • KSI data problem: The report’s “killed or seriously injured” comparison uses inconsistent definitions, pairing a broad NYPD severity measure with the Taxi and Limousine Commission’s narrower “critical injury” category.
  • Waymo’s serious crashes: Waymo recorded three KSI crashes over 220 million driverless miles; its two fatal crashes involved people outside the autonomous vehicles, and Waymo was not blamed for either death.
  • Professional-driver benchmark: Adjusting for comparable injury definitions would imply roughly 190 KSI crashes among for-hire vehicles rather than 16, making Waymo’s reported rate substantially lower.
  • Congestion claims: Empty-mile rates depend heavily on trip density and service area; replacing yellow taxis, which are empty 59 percent of the time, with robotaxis could reduce total vehicle miles.
  • Policy recommendation: New York should require transparent public reporting and consistent crash definitions while allowing further autonomous-vehicle testing instead of maintaining a de facto ban.



New York’s public transit advocacy community has launched a new attack against robotaxis. A recently published report from Open Plans and the Sam Schwartz Transportation Program leads with an alarming claim: Waymo vehicles, they assert, “have a significantly higher rate of crashes with a serious injury or fatality than the existing New York City for-hire fleet.”

The full report largely concedes the point that robotaxis are safer than the typical human driver (an earlier point of debate) and instead focuses on the comparison with for-hire services like Uber, Lyft, and yellow taxis. Concern about the impact on jobs in this sector is the main reason that autonomous vehicles remain illegal in New York. (Waymo’s limited testing permit lapsed in March.)

But a closer look at what the report actually found shows that the safety record of robotaxis is so strong that they clear even the bar of safety compared with professional drivers in the Big Apple. Unfortunately, the report skewed the numbers to push the authors’ preferred narrative.

The study’s strongest statistical analysis looks at the risk of injury-causing crashes among different vehicle types. These data are taken from Waymo’s reporting to federal regulators and crash data from the NYPD indicating injuries or fatalities. Over 40,000 such cases occur in New York City in a typical year, allowing for a statistically sound comparison against Waymo’s record, whether deployed in San Francisco or nationwide.

The report’s key finding is that Waymos are involved in far fewer injury-causing crashes than either New York City drivers or for-hire vehicles: 0.71 crashes per million miles nationally compared with 2.15 for New York City’s taxis, Ubers, and Lyfts. This is especially striking because New York City’s lower speed limits and other infrastructure substantially reduce accidents relative to the national average. Waymo has reached a safety level that exceeds even that of New York City’s professional drivers. In fact, the authors found that Uber and Lyft drivers have slightly higher crash rates than other drivers, and yellow cab drivers have even higher crash rates than Uber and Lyft drivers. This may not be surprising because Uber and Lyft’s rating system allows for a greater reputational record than yellow taxis.

When we turn to more serious accidents resulting in death—which Vision Zero intends to eliminate—New York City has a far lower auto fatality rate than the rest of the country but still sees over 200 auto deaths a year. In a comparison of fatal crashes, Waymo, all-city drivers, and for-hire vehicles are essentially tied. Yellow taxis are slightly more deadly than New York drivers in general, while Uber and Lyft are slightly less deadly. However, given the sparse data, it’s hard to tell exactly what’s going on.

Even when judged against professional drivers in New York City—a highly demanding benchmark—and even when compared using fatalities, Waymo has a superior or similar record. The report’s authors nonetheless conclude otherwise based entirely on an analysis of “Killed or Seriously Injured” (KSI).

Waymo’s entire KSI record—across 220 million driverless miles since 2020—consists of just three crashes. New York’s for-hire fleet had 16 over 1.75 billion miles in 2025. Analyzing a variable this rare doesn’t tell us much. The report, to its credit, published 95 percent confidence intervals, which show that the crash rate for New York City’s for-hire fleet is 0.005–0.015, which overlaps with a value of 0.003–0.040 for Waymo nationally and 0.004–0.108 for the Bay Area. The authors wrote that “the data cannot rule out Waymo having a comparable KSI rate.”

A deeper look at the data makes the picture even more favorable to Waymo. The serious-injury record for Waymo includes just two fatal crashes. But in neither accident was the killed passenger riding in the autonomous vehicle. In one case, a Waymo robotaxi in San Francisco was rear-ended while completely stopped and then hit other vehicles in a multi-car collision, killing one person. In the other case, a motorcyclist hit a Waymo that was signaling a turn and yielding to a pedestrian; the cyclist was then struck by another vehicle and later died.

While these cases are tragic, Waymo was not blamed for the crashes. In fact, Waymo has been judged at fault in a tiny fraction of the accidents it has been involved in —less than 5 percent, according to one analysis.

Even including fatalities Waymo wasn’t responsible for, Waymo is still statistically much safer than New York City drivers overall. It is only at parity with for-hire drivers, who are about ten times less risky than all drivers in Open Plans’ analysis on KSI. This finding should cause some confusion. If yellow taxi drivers cause more crashes with injuries than all drivers—and lead to more fatalities than all drivers—how do they show up as ten times less risky in an analysis on serious injuries?

The problem here lies in a comparison of two dissimilar sources, as Jonathan Nolan has pointed out. The all-vehicle KSI measure (3,188 crashes) comes from applying a “modified New York State Department of Motor Vehicles (NYS DMV) severity formula” to raw NYPD collision records. This is a broad severity category that includes everything from concussions, fractures, severe lacerations, internal injuries, semiconsciousness, etc.

But for for-hire vehicles, the report uses data from the Taxi and Limousine Commission, which mandates crash reporting for licensed vehicles, where the relevant category from Local Law 31 is critical injury. This is defined as a “severe injury that poses an immediate threat to life or is likely to cause long-term impairment or disability.” These two categories are not comparable.

A simple way to see the mismatch is to examine the implied ratio of serious-injury crashes to fatal crashes. For all New York City vehicles, it’s about 13 to 1 (3,188 KSI to 252 fatal). With professional drivers, it’s 1.07 to 1 (16 to 15). If you take the data literally, it suggests that taxi drivers almost never seriously injure someone without also killing them, which is both physically absurd and exactly what you would expect if the “serious injury” definition for for-hire vehicles is actually measuring closer to fatality.

Suppose we instead make a simple assumption: that for-hire vehicles result in serious injuries in the same proportion to deaths as the citywide fleet. That would imply roughly 190 KSI crashes, not 16, at a rate of 0.11 per million miles. By that measure, Waymo, at 0.014 nationally, is not 1.5 times worse than the professionals (as the report claims), but about eight times better.

To be sure, accurately assessing the risk of for-hire vehicles against the citywide average (including speeding teenagers, drunk drivers, and motorcycles) is a challenging task. Professional drivers have higher reporting requirements for accidents, which might put them at a disadvantage against all drivers in this comparison. It’s plausible that professional drivers may indeed be slightly safer when measured against some categories of injury. But Waymo easily clears this benchmark as long as comparable statistics are used. While assessing the true impacts on mortality will take more time, we can still reason from the substantial improvements in milder accidents that safety is getting better.

The report’s second argument is that robotaxis will worsen congestion. While this may happen, the arguments used here are similarly tenuous.

The comparison is between Waymo’s fleet, which drives empty 42 percent of the time, versus 33 percent for New York City’s Uber and Lyfts. However, this compares Waymo’s operations in a sprawling, lower-density service area against one of the densest ride-hail markets on earth. “Deadheading,” as it’s called, is the result of trip density, not whether a person or a robot is driving the car. If we deploy Waymo’s fleet in Manhattan, we will see the share of empty miles fall.

Robotaxis might even improve the situation. The report finds that yellow taxis are empty 59 percent of the time, and that they drive empty for 1.43 miles for each mile that they have a passenger. By that logic, replacing yellow taxis with robotaxis (even at the utilization rate they achieve in places like California) would reduce miles travelled by nearly a third. This finding highlights an unintended benefit of ride-hailing technologies like Uber, Lyft, or Waymo: by reducing the need for yellow taxis to circle the streets to find passengers, they can substantially reduce congestion.

While its streets are indeed safer than those of other major cities, New York still recorded 205 traffic deaths last year and tens of thousands of injuries, overwhelmingly caused by driver error. Robotaxis would lower this rate, if not to zero, then to something much closer to it.

Waymo’s technology isn’t perfect and needs additional testing on city roads and improvements over time. However, state law still requires a human driver behind the wheel, and Waymo’s modest safety-driver permit expired in March, with no follow-up framework. And the local policy conversation is being shaped by reports, such as the one from Open Plans, that paint a misleading picture of Waymo’s true safety record. Albany simultaneously demands that Waymo provide a statistical certainty of safety that is only possible after many billions of miles while prohibiting Waymo from actually producing that record.

Some of the report’s recommendations are reasonable and should be supported. Requiring public-data reporting from operators is reasonable, and the city should provide TLC and NYPD crash data using consistent definitions to provide clearer benchmarks. But what New York has chosen instead is a ban through paralysis. New Yorkers should not let three crashes in the rest of the country determine the future of their streets.

Donate

City Journal is a publication of the Manhattan Institute for Policy Research (MI), a leading free-market think tank. Are you interested in supporting the magazine? As a 501(c)(3) nonprofit, donations in support of MI and City Journal are fully tax-deductible as provided by law (EIN #13-2912529).



Read the whole story
bogorad
16 hours ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

The Pentagon Should Buy the Weapons It Needs, Not Tell Companies What to Build

1 Share
  • Defense-industrial weaknesses: Inadequate production capacity, reduced competition, vulnerable supply chains, and lengthy delays have left major weapons programs late and over budget.
  • Section 815 proposal: The Senate’s 2027 National Defense Authorization Act would bar Pentagon contracts with companies that repurchase publicly traded shares or make other capital distributions, including dividends, unless they receive approval.
  • Questionable assumption: Preventing shareholder distributions would not necessarily turn retained cash into productive defense investment; companies might hold cash, repay debt, pursue acquisitions, raise compensation, or fund unproductive projects.
  • Evidence on buybacks: Financial research generally finds that firms distribute excess capital after addressing investment and liquidity needs, while repurchasing companies do not systematically reduce capital expenditures, research, development, or employment.
  • Unintended consequences: The restriction could encourage waiver-seeking and spending designed to fit statutory categories, deter diversified and dual-use suppliers, raise bids, reduce competition, and increase financing costs.
  • More direct procurement tools: Multiyear purchase commitments, capacity-reservation contracts, advance commitments, milestone financing, co-investment, and cost sharing would more directly pay for the capacity, delivery, and surge capability the Pentagon needs.



America’s defense-industrial base has real problems. Production capacity is inadequate in critical areas, competition has declined, and supply chains remain vulnerable. Important weapons systems arrive late and over budget: the Government Accountability Office’s 2026 assessment found persistent schedule delays across major programs and an average delivery time exceeding 12 years. Contractors and government officials share blame for these failures.

But not all solutions to the problem are equal. Section 815 of the Senate’s version of the 2027 National Defense Authorization Act tries to solve the problem by barring the Pentagon from contracting with a company unless the contractor agrees not to repurchase its publicly traded shares or other capital distributions, including dividends.

The proposal has bipartisan support and an intelligible premise: money returned to shareholders is money that could instead expand production. But the idea rests on a faulty assumption: that the cash a contractor can’t distribute in the form of stock buybacks or dividends will become productive defense investment. Neither standard corporate-finance theory nor evidence supports that assumption. Congress should, therefore, look elsewhere for fixes to our defense-industrial base.

In standard theory, companies ordinarily decide which projects are worth undertaking first, then how much liquidity they need, and only afterward what to do with any remaining cash. When a firm lacks additional projects expected to earn more than their cost of capital, it may distribute the excess to investors, who can redeploy the funds elsewhere. A dollar retained by a corporation is therefore not necessarily a dollar invested productively. It may remain as cash, pay down debt, finance an acquisition, increase compensation, or perhaps worst of all, support a project whose expected return does not justify its cost.

The leading empirical studies generally support this account. Alon Brav, John Graham, Campbell Harvey, and Roni Michaely found that financial executives typically viewed distributions as residual—that is, made after investment and liquidity needs had been met. Jesse Fried and Charles Wang showed that claims that public companies distributed nearly all their earnings ignored the capital flowing back through equity issuances. Once those inflows were counted, net shareholder payouts were much lower, while investment and cash balances both increased.

Other studies find that repurchasing firms often face declining growth opportunities, a pattern consistent with mature companies returning capital after attractive opportunities diminish. Paul Brockman, Hye Seung Lee, and Jesus Salas likewise find no evidence that repurchasing firms systematically reduce capital expenditures, research and development, or employment after accounting for their opportunity sets. These findings accord with Michael Jensen’s account of the agency costs of free cash flow: managers sometimes control more cash than they can deploy productively, and returning excess capital can help prevent empire-building and poor acquisitions.

These findings do not vindicate every repurchase. Research shows that managers sometimes sacrifice investment opportunities to meet earnings-per-share targets or to support the price at which executives sell their own shares. But those studies support targeted responses—not Section 815’s enterprise-wide rule, which would apply without regard to earnings targets, compensation design, insider sales, the price paid for shares, the contractor’s investment opportunities, or the performance of the contract that triggers the restriction.

Indeed, Section 815 reverses the ordinary presumption that boards may return excess cash to shareholders when there are no efficient investment opportunities. Unless the Pentagon approves a qualifying investment plan, a contractor who wishes to continue doing business with the government must retain capital it otherwise would have distributed. The provision thus transfers part of the authority to allocate corporate capital from boards and markets to procurement officials.

The strongest argument for Section 815 is that defense production is not an ordinary market. Capacity can be expensive and difficult to rebuild. A production line may have substantial national-security value even when it does not promise an adequate private return. Contractors may rationally hesitate to invest when appropriations are uncertain, orders fluctuate, technical requirements change, or the government will not commit to buying the resulting output.

But all of these are contracting problems, not payout problems. Preventing a dividend does not make future demand more predictable, compensate a firm for maintaining idle capacity, resolve technical uncertainty, or identify which expenditure would relieve a genuine production constraint. Nor does it create a positive-return project where none exists. A diversified contractor may retain the money and use it elsewhere, repay debt, acquire another business, or simply hold more cash.

Nor does Section 815’s waiver mechanism—which applies to contractors with an approved defense-investment plan covering facilities, equipment, research, workforce training, or strategic stockpiles—solve this problem. It requires the Pentagon to decide not only what product it wants, at what price, and on what schedule, but also whether a contractor’s proposed investment plan justifies permitting firm-wide dividends or repurchases. Those judgments require forecasts about demand, financing, opportunity cost, and investment returns that procurement officials are poorly positioned to make. The process will also favor expenditures that fit statutory categories, not necessarily those that create the greatest value.

Section 815 is also likely to generate costly reactions. Contractors will devote resources to obtaining waivers, reclassify ordinary spending as qualifying investment, and select projects that satisfy statutory categories. Some firms—especially diversified companies, for which defense sales are small—may decide that Pentagon work is not worth an enterprise-wide restriction on financial policy. This could deter the commercial entrants and dual-use suppliers that policymakers otherwise seek to attract. The remaining contractors’ added costs will appear in higher bids, reduced entry, a less diverse supplier base, more conservative financing, and a higher cost of capital.

The more direct response is for the Pentagon to contract for the capacity the government values. Multiyear purchase commitments can reduce demand risk. Capacity-reservation contracts can pay firms to maintain surge capability. Advance commitments, milestone financing, co-investment, and cost sharing can make socially valuable investments privately worthwhile. These tools address the reason a contractor may decline to invest far better than a payout prohibition would.

Section 815 originates from a legitimate concern: national defense should not suffer because contractors prefer short-term financial rewards to necessary investment. The evidence confirms that distorted repurchases can occur, but it does not show that payouts generally crowd out productive investment, or that preventing a distribution will convert retained cash into factories, research, or weapons.

Congress should condition defense contracts on the capacity, cost, and delivery it needs, and tie consequences to actual underperformance. Section 815 instead regulates an observable financial decision because it is easier to police than the procurement failures Congress wants to correct. That’s a weak substitute for procurement reform—and a consequential expansion of political authority over private capital allocation.

Donate

City Journal is a publication of the Manhattan Institute for Policy Research (MI), a leading free-market think tank. Are you interested in supporting the magazine? As a 501(c)(3) nonprofit, donations in support of MI and City Journal are fully tax-deductible as provided by law (EIN #13-2912529).



Read the whole story
bogorad
20 hours ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

PART ONE: The way we run vaccine clinical trials is bizarre, unethical, and must change

1 Share

LLM (google/gemini-3.1-flash-lite) summary:

  • Standard Protocols: randomized placebo controlled trials represent the primary method for evaluating medical efficacy and identifying side effects.
  • Vaccine Methodology: vaccine clinical trials frequently deviate from standard drug testing by utilizing active comparators instead of inert placebos.
  • Active Comparator Issue: relying on other vaccines as control groups obscures the true incidence and severity of adverse reactions associated with the new product.
  • Trial Bias: the current testing design creates an incentive for approval by inflating the risk profile of control groups to minimize the appearance of vaccine related side effects.
  • Prophylactic Consideration: vaccine safety data requires increased rigor because these products are administered to healthy populations rather than individuals seeking treatment for acute illness.
  • Unblinding Justifications: claims that saline placebos cause functional unblinding in trials are rejected as insufficient, noting that other drug classes manage similar risks without substituting active controls.
  • Ethical Misconceptions: the argument that trial participants must receive an active treatment to maintain ethical standards contradicts the fundamental objective of conducting objective research for future patient benefit.
  • Regulatory Stagnation: proposed reforms to align vaccine approval standards with general medical regulations remain unimplemented despite advocacy from external reformers.

(Part 1: The trouble with vaccine trials)

Randomized placebo-controlled trials are the heart of medicine. They’re how doctors know new treatments work and have acceptable side effects compared to their benefits.

Except for vaccines. Vaccine trials often use a different, lower standard that makes it impossible to tell how serious their side effects are.

The loophole is especially bizarre because most vaccines are not given to sick people who need immediate help but prophylactically to healthy children.

Last year, Robert F. Kennedy Jr. and Food and Drug Administration reformers promised to make vaccines follow the same standards as other medicines. But, after loud and misleading pushback from reporters, health bureaucrats, and drug companies, the FDA didn’t.

Now the reformers have been run out of town. And kids and adults will continue to be pushed (or sometimes forced) to use vaccines approved without honest safety data.

(Honest explanations, no matter how painful they may be. The truths you won’t see anywhere else. Support this work, for pennies a day.)

So how does this loophole work?

Clinical trials typically split patients into two groups. One receives the new medicine being investigated. The other gets either an older treatment for the same disease or, if no older drug exists, a placebo, like a sugar pill or saline shot.

Because the patients are split at random before receiving the treatment, scientists can assume changes afterwards come from the treatment itself — not from some hidden difference between patients who take the drug and those who don’t.

That’s why clinical trials are as close to proof that a medicine has real benefit as we can get. (This is, of course, a major oversimplification about how clinical trials and drug development work. For more information, read this footnote.1)

But clinical trials don’t just measure benefits. All medicines have side effects. Trials let regulators, doctors, and patients see how a new drug’s risks compare to a placebo or older medicine.

But vaccine trials frequently have a crucial difference from those used for other medicines.

In vaccine trials, instead of testing new jabs against placebos, drug companies often use what they call “active comparators” — other vaccines.

To be clear, these are not situations where companies are testing new vaccines for diseases like measles, where older jabs for the same disease already exist. In those cases, it may be unethical to offer a true placebo arm.2

These are trials for entirely new vaccines treating diseases for which no approved treatment exists.3 In this case, the comparator is typically a vaccine for a different disease, one the trial is not testing.

(I said sugar pill, not Skittles!)

For example, in the pivotal 37,000-infant trial of PCV7, a vaccine against bacteria that can cause pneumonia and ear infections, infants and toddlers were given multiple shots of PCV7 or a vaccine against meningitis that itself wasn’t even approved at the time.

The effect of this sleight-of-hand is to make side effects for the vaccine being tested seem far more modest than they are, since the “active comparator” vaccine will have much worse side effects than a saline shot would.

Imagine a test that compared injuries from being hit by a sledgehammer to those from a baseball bat, instead of a sledgehammer and a styrofoam sledgehammer.

In turn, that deception fundamentally biases the trial to favor approval, since the FDA is of course supposed to consider side effect profiles when deciding on new products.

And side effects should be especially important in considering vaccine approval, since vaccines are usually given to healthy children or teens who often face a minimal risk of ever becoming gravely ill from the disease the shot is supposed to prevent.

(Another colorful graphic. So much science-y science! So many new pneumococcal vaccines. Too bad they forgot the placebos.)

In a 2014 paper in the journal Vaccine, a World Health Organization scientific working group wrote that “randomized, placebo-controlled trials are widely considered the gold standard for evaluating the safety and efficacy of a new vaccine.” (The WHO was considering whether placebo trials are acceptable even when a working vaccine already exists. It found that many times even in that case the answer was yes).

So why are vaccines different? Why are placebo-controlled trials not required in every instance?

Their advocates offer two primary justifications. Neither holds up.

The first is that vaccines have such intense side effects that using saline will tip people in the trial to whether they are getting the vaccine or the placebo — it will “functionally unblind” the trial and bias the outcomes.

But the same potential unblinding holds for non-vaccine medicines. Many antidepressants have sexual side effects, for example, but no one suggests that men in the placebo arms of antidepressant trials be given blood pressure medicines (which can cause impotence).

Ready to support Unreported Truths but not ready to subscribe? Try a one-time $5 donation (or more, if you like!)

Further, the fact that vaccines cause such serious side effects that the only possible way to keep a trial blinded is to use other vaccines in placebo arms is hardly a general argument for vaccine safety.

Finally, many vaccines are given to infants and toddlers — who will have no way of knowing they are in a clinical trial, much less realizing that the side effects they suffer are the result of a vaccine. In other words, the risk of functional unblinding should be lower, not higher, in trials for kids.

The second justification is that everyone participating in a vaccine trials “deserves” the benefit of some vaccine for participating. Last year, Dr. Steven Black, the lead investigator in the PCV7 trial, told PBS the trial had not been placebo controlled

due to the ethical concern of requiring the more than 15,000 control patients in the trial having to receive four doses of a placebo vaccine with no potential for benefit.

This is… not how clinical trials work. As Dr. Black should know.

The point of a clinical trial is not to benefit the people in it. Yes, they may benefit from getting a new treatment that other people haven’t received. But they may also be harmed, if the drug does not work or has severe side effects.

The point of running the trial is to test the medicine and find out. It is to gain information that will help future patients, not the ones in the trial.

This is one reason that researchers are strongly discouraged from enrolling prisoners or other people at risk of feeling coerced into joining clinical trials. Offering large payments is also unacceptable, though small ones for time and inconvenience are reasonable. (In very-early stage trials where a few healthy people face the risk of a compound never before tested in human beings, payments can be higher.)

In other words, potential trialists (or their parents, in the case of trials for children) should join trials freely, without hoping for any benefit other than the potential gain from a new drug — and the chance to altruistically help science and medicine.

This potential lack of benefit may seem wrong at first.

It’s not.

Not as long as no one is forced to participate in a trial, doctors clearly explain the potential risks and benefits to the people who enroll, and the people running the trial have a reasonable belief that the new drug will work and isn’t too risky.

We need clinical trials. Without them, all we have is guesswork.

And without true placebo arms, clinical trials are far less valuable, if not close to useless.

(Support work like this. Please.)

The key fact here, the one that vaccine advocates seem to forget: Vaccines are no different than other drug classes. They aren’t magic. Doctors, regulators, and most of all the people who receive them deserve clean and reliable information about them, including their side effects — just as they do with other drugs.

That’s what Dr. Vinay Prasad tried to say in November, when, as the chief medical officer of the FDA, he wrote in a memo that “vaccines will be treated like all other medication classes.”

And that’s what Robert F. Kennedy promised in April 2025, when he said the FDA would require placebo-controlled clinical trials for vaccines.

But Prasad is gone. And the FDA’s guidance on vaccines remains unchanged.

That’s not an accident.

(First of two parts. Coming soon: the misleading pushback from the media and health bureaucrats that derailed vaccine trial reform.)

1

In general, the development of new medicines progresses in three stages in humans.

In the first stage, a company gives a new compound to a few healthy volunteers to make sure it doesn’t unexpectedly kill anyone. In the second, which can cover anywhere from a few dozen to a few hundred people, the company figures out the best dose, the one that will have the most impact on the disease with the fewest side effects.

Then, in the third or pivotal stage, the company tests that dose in a large trial or trials, hoping to prove its medicine or vaccine will have a “statistically significant” impact on the disease.

The outcome being measured doesn’t necessarily have to be deaths or hospitalizations; an anti-migraine drug might be tested to see if it reduces the number of days each month a person has migraines. If the drug hits the goal the company has set in a way that is unlikely to be due to chance, the trial has succeeded and the drug is approvable — assuming its side effects are not too bad.

Even this length explanation deeply oversimplifies the drug development process and elides many crucial details. For example, a very large trial may be able to capture small differences between a drug and placebo, enabling a company to submit a drug for approval even if it may make little real world difference to patients. Or a company hoping to speed the process may begin the third, largest stage before finishing the second.

Further, in the case of diseases that are very rare or invariably fatal or both, regulators may accept less rigorous trial designs — a seemingly compassionate choice that has often led to later grief.

2

Even then the trial ethics are somewhat complex, because the effectiveness of new treatments can subtly decline over multiple generations of seemingly successful trials, ultimately leading to the introduction of new drugs that don’t work as well as older ones.

3

The mRNA Covid vaccine trials were a rare example of a trial for a novel vaccine run against true saline placebo. And not surprisingly, people who received the mRNA reported much severer side effects than those who given saline.

Read the whole story
bogorad
1 day ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete
Next Page of Stories